These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Enzyme replacement therapy for mucopolysaccharidosis II from 3 months of age: a 3-year follow-up. Tylki-Szymanska A; Jurecka A; Zuber Z; Rozdzynska A; Marucha J; Czartoryska B Acta Paediatr; 2012 Jan; 101(1):e42-7. PubMed ID: 21672014 [TBL] [Abstract][Full Text] [Related]
23. Evidence and values: requirements for public reimbursement of drugs for rare diseases--a case study in oncology. Drummond M; Evans B; LeLorier J; Karakiewicz P; Martin D; Tugwell P; MacLeod S Can J Clin Pharmacol; 2009; 16(2):e273-81; discussion e282-4. PubMed ID: 19439771 [TBL] [Abstract][Full Text] [Related]
24. Characteristic "pebbling" skin eruption as a presenting sign of Hunter syndrome. Noh TK; Han JS; Won CH; Chang S; Choi JH; Moon KC; Lee MW; Yang JH; Soung JH Int J Dermatol; 2014 Dec; 53(12):e594-6. PubMed ID: 25267496 [No Abstract] [Full Text] [Related]
25. Mucopolysaccharidosis type II, Hunter's syndrome. Tylki-Szymańska A Pediatr Endocrinol Rev; 2014 Sep; 12 Suppl 1():107-13. PubMed ID: 25345092 [TBL] [Abstract][Full Text] [Related]
26. Toward a functional definition of a "rare disease" for regulatory authorities and funding agencies. Clarke JT; Coyle D; Evans G; Martin J; Winquist E Value Health; 2014 Dec; 17(8):757-61. PubMed ID: 25498770 [TBL] [Abstract][Full Text] [Related]
27. Hunter disease before and during enzyme replacement therapy. Hoffmann B; Schulze-Frenking G; Al-Sawaf S; Beck M; Mayatepek E Pediatr Neurol; 2011 Sep; 45(3):181-4. PubMed ID: 21824567 [TBL] [Abstract][Full Text] [Related]
28. Impact of a novel prioritization framework on clinician-led oncology drug submissions. Keech J; Beca J; Eisen A; Kennedy E; Kim J; Kouroukis CT; Darling G; Ferguson SE; Finelli A; Petrella TM; Perry JR; Chan K; Gavura S Curr Oncol; 2019 Apr; 26(2):e155-e161. PubMed ID: 31043821 [TBL] [Abstract][Full Text] [Related]
29. Glycosaminoglycans can be associated with oxidative damage in mucopolysaccharidosis II patients submitted to enzyme replacement therapy. Negretto GW; Deon M; Biancini GB; Burin MG; Giugliani R; Vargas CR Cell Biol Toxicol; 2014 Aug; 30(4):189-93. PubMed ID: 25022704 [No Abstract] [Full Text] [Related]
30. The management of children with Hunter syndrome - a case study. Little C; Gould R; Hendriksz C Br J Nurs; 2009 Mar 12-25; 18(5):321-2. PubMed ID: 19273994 [TBL] [Abstract][Full Text] [Related]
31. Improvement of cardiac function by short-term enzyme replacement therapy in a murine model of cardiomyopathy associated with Hunter syndrome evaluated by serial echocardiography with speckle tracking 2-D strain analysis. Lee SC; Lee J; Jin DK; Kim JS; Jeon ES; Kwun YH; Chang MS; Ko AR; Yook YJ; Sohn YB Mol Genet Metab; 2014 Jul; 112(3):218-23. PubMed ID: 24836711 [TBL] [Abstract][Full Text] [Related]
32. Home treatment with intravenous enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II - data from the Hunter Outcome Survey. Burton BK; Guffon N; Roberts J; van der Ploeg AT; Jones SA; Mol Genet Metab; 2010; 101(2-3):123-9. PubMed ID: 20638311 [TBL] [Abstract][Full Text] [Related]
33. Effects of idursulfase enzyme replacement therapy for Mucopolysaccharidosis type II when started in early infancy: comparison in two siblings. Tajima G; Sakura N; Kosuga M; Okuyama T; Kobayashi M Mol Genet Metab; 2013 Mar; 108(3):172-7. PubMed ID: 23375472 [TBL] [Abstract][Full Text] [Related]
34. Early response to idursulfase treatment in a 3 year-old boy affected of Hunter syndrome. Galán-Gómez E; Guerrero-Rico A; Cáceres-Marzal C; Zambrano-Castaño M; Moreno-Tejero ML; Grande-Tejada AM; Fernández-Hernández S; Vaquerizo-Madrid J; Cardesa-García JJ Eur J Med Genet; 2008; 51(3):268-71. PubMed ID: 18396123 [TBL] [Abstract][Full Text] [Related]
35. Ethical issues in funding orphan drug research and development. Gericke CA; Riesberg A; Busse R J Med Ethics; 2005 Mar; 31(3):164-8. PubMed ID: 15738438 [TBL] [Abstract][Full Text] [Related]
36. A discrete choice experiment investigating preferences for funding drugs used to treat orphan diseases: an exploratory study. Mentzakis E; Stefanowska P; Hurley J Health Econ Policy Law; 2011 Jul; 6(3):405-33. PubMed ID: 21205401 [TBL] [Abstract][Full Text] [Related]
37. Parental experience of enzyme replacement therapy for Hunter syndrome. Buraczewska M; O'Leary D; Walsh O; Monavari A; Crushell E Ir Med J; 2013 Apr; 106(4):120-2. PubMed ID: 23691848 [TBL] [Abstract][Full Text] [Related]
38. A fair share for the orphans: ethical guidelines for a fair distribution of resources within the bounds of the 10-year-old European Orphan Drug Regulation. Pinxten W; Denier Y; Dooms M; Cassiman JJ; Dierickx K J Med Ethics; 2012 Mar; 38(3):148-53. PubMed ID: 21947805 [TBL] [Abstract][Full Text] [Related]
39. Funding new cancer drugs in Ontario: closing the loop in the practice guidelines development cycle. Pater JL; Browman GP; Brouwers MC; Nefsky MF; Evans WK; Cowan DH J Clin Oncol; 2001 Jul; 19(14):3392-6. PubMed ID: 11454887 [TBL] [Abstract][Full Text] [Related]
40. [Clinical practice guideline for the management of Hunter syndrome. Hunter España working group]. Guillén-Navarro E; Blasco AJ; Gutierrez-Solana LG; Couce ML; Cancho-Candela R; Lázaro P; Med Clin (Barc); 2013 Nov; 141(10):453.e1-13. PubMed ID: 24060500 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]